Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.
NCT ID: NCT02710890
Last Updated: 2023-02-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
103 participants
INTERVENTIONAL
2017-05-30
2019-06-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures
NCT01964560
A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.
NCT01969851
Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures
NCT02477839
Pediatric Epilepsy Study in Subjects 1-24 Months
NCT00044278
Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures
NCT01921205
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lacosamide
Up to 2 age-based Cohorts with Cohort 1 including at least 40 subjects who are \>=8 to \<17 years. For Cohort 2 every attempt will be made to enroll 20 subjects \>= 4 to \< 8 years of age, 12 subjects \>= 2 to \< 4 years of age and 12 subjects \>= 1 month to \< 2 years of age. A Data Monitoring Committee (DMC) will review the safety and tolerability data for each Cohort to make the following recommendations: the progression of the current Cohort, including intravenous (iv) infusion durations to be evaluated, and progression to initiate enrollment in the next Cohort (Cohort 2).
Lacosamide
Pharmaceutical form: solution for infusion
Concentration: 10 mg/ml
Route of Administration: intravenous
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lacosamide
Pharmaceutical form: solution for infusion
Concentration: 10 mg/ml
Route of Administration: intravenous
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has a diagnosis of epilepsy with partial-onset seizures or primary generalized tonic-clonic seizures
* Subject meets 1 of the following criteria:
1. Open-label lacosmide (OLL) subject: Subject is currently receiving oral lacosmide (LCM) as adjunctive or monotherapy as participants in an open label long-term study (SP848, EP0034, or other pediatric study); OR,
2. Prescription lacosamide (RxL) subject: Subject is currently receiving prescribed oral LCM from commercial supply (eg, VIMPAT) as adjunctive or monotherapy; OR,
3. Initiating intravenous lacosamide (IIL) subject: Subject is not currently receiving LCM and will receive intravenous (iv) LCM as adjunctive treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL subjects.
* Subject is an OLL or RxL subject and meets both of the following criteria:
1. Subject has been administered LCM for the treatment of epilepsy for at least 2 weeks prior to Screening; AND
2. Subject has been administered (OLL) or prescribed (RxL) oral LCM at a dose of 2 mg/kg/day to 12 mg/kg/day (for subjects \<50 kg) or 100 mg/day to 600 mg/day (for subjects \>=50 kg). Open-label study drug LCM (OLL) or prescribed oral LCM dose (RxL) must be stable for at least 3 days prior to first LCM infusion; OR,
* Subject is an ILL subject and is on a stable dosage regimen of at least 1 antiepileptic drug (AED). The daily dosage regimen of concomitant AED therapy must be kept constant for a period of at least 2 weeks prior to Screening.
* Subject is an acceptable candidate for venipuncture and iv infusion
* Subject is, in the opinion of the investigator, able to comply with all study requirements. Subject (or parent\[s\] or legal representative) is willing to comply with all study requirements
* Subject weighs \>=4 kg
Exclusion Criteria
* Subject has any medical, neurological, or psychiatric condition that, in the opinion of the investigator, could jeopardize the subject's health or compromise the subject's ability to participate in EP0060
* Subject has clinically significant hypotension or bradycardia in the opinion of the investigator
* Subject \>=6 years of age has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by positive responses ("Yes") to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening
For open-label lacosamide (OLL) subjects, enrollment in EP0060 is not permitted if any of the following additional criteria are met:
\- Subject has any ongoing Adverse Event (AE) in their long-term, open-label study that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate EP0060 or the subject meets any of the criteria for required withdrawal from the long-term open-label study
For prescription lacosamide (RxL) and initiating intravenous lacosamide (IIL) subjects, enrollment in EP0060 is not permitted if any of the following additional criteria are met:
* Subject has a medical condition that could reasonably be expected to interfere with drug absorption distribution, metabolism, or excretion
* Subject is a female of childbearing potential and does not practice an acceptable method of contraception for the duration of participation in EP0060
* Subject has creatinine clearance less than 30 mL/min
* Subject has a clinically relevant electrocardiogram (ECG) abnormality, in the opinion of the principal investigator (ie, second or third degree heart block at rest or a QT prolongation greater than 450 ms)
* Subject has hemodynamically significant heart disease (eg, heart failure)
* Subject has an arrhythmic heart condition requiring medical therapy, known cardiac sodium channelopathy, such as Brugada syndrome
* Subject has a known history of severe anaphylactic reaction or serious blood dyscrasias
* Subject has an acute or subacutely progressive central nervous system disease.
* Subject has epilepsy secondary to a progressing cerebral disease or any other progressive or neurodegenerative disease (malignant brain tumor or Rasmussen syndrome)
* Lacosamide is intended for treatment of generalized convulsive status epilepticus
* Subject has diagnosis of Dravet's syndrome
For IIL subjects, enrollment in EP0060 is not permitted if the following additional criterion is met:
\- Subject has been treated with LCM within the last 3 months prior to Screening
1 Month
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB BIOSCIENCES, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Cares
Role: STUDY_DIRECTOR
+1 8445992273 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ep0060 003
Birmingham, Alabama, United States
Ep0060 010
Little Rock, Arkansas, United States
Ep0060 008
Loxahatchee Groves, Florida, United States
Ep0060 009
Saint Paul, Minnesota, United States
Ep0060 014
Henderson, Nevada, United States
Ep0060 002
New Brunswick, New Jersey, United States
Ep0060 006
Akron, Ohio, United States
Ep0060 011
Cincinnati, Ohio, United States
Ep0060 005
Dallas, Texas, United States
Ep0060 007
San Antonio, Texas, United States
Ep0060 400
Budapest, , Hungary
Ep0060 401
Debrecen, , Hungary
Ep0060 503
Messina, , Italy
Ep0060 505
Roma, , Italy
Ep0060 502
Verona, , Italy
Ep0060 701
Krakow, , Poland
Ep0060 224
Dnipro, , Ukraine
Ep0060 225
Dnipro, , Ukraine
Ep0060 220
Ivano-Frankivsk, , Ukraine
Ep0060 221
Kiev, , Ukraine
Ep0060 222
Kiev, , Ukraine
Ep0060 226
Kiev, , Ukraine
Ep0060 223
Vinnytsia, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Farkas MK, Beller C, Bozorg A, McClung C, Roebling R, Yates T, Yuen N, Makedonska I. Safety and tolerability of short-term infusions of intravenous lacosamide in pediatric patients with epilepsy: An open-label, phase 2/3 trial. Epilepsia Open. 2023 Mar;8(1):146-153. doi: 10.1002/epi4.12682. Epub 2023 Jan 18.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-003294-42
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
EP0060
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.